A problem-oriented approach to liver disease in oncology patients

Gut

Volumn 57, Issue 7, 2008, Pages 987-1003

  McDonald, George B ^a,b,d   Frieze, D ^a,c  

^a SEATTLE CANCER CARE ALLIANCE   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; ASPARAGINASE; BORTEZOMIB; BUSULFAN; CARBOPLATIN; CARMUSTINE; CHLOROZOTOCIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYPROTERONE ACETATE; CYTARABINE; DACARBAZINE; DACTINOMYCIN; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; FLOXURIDINE; FLUTAMIDE; GEMCITABINE; GEMTUZUMAB OZOGAMICIN; IMATINIB; INTERLEUKIN 2; LOMUSTINE; MERCAPTOPURINE; METHOTREXATE; MITHRAMYCIN; TIOGUANINE; UNINDEXED DRUG;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADENOVIRUS; ALGORITHM; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CHOLESTASIS; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC HEPATITIS; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL DECISION MAKING; COLORECTAL CANCER; COMORBIDITY; CYTOMEGALOVIRUS; DOSE CALCULATION; DRUG CHOICE; DRUG FATALITY; DRUG METABOLISM; DRUG MONITORING; EPSTEIN BARR VIRUS; FATTY LIVER; GALLSTONE; HEAD AND NECK CARCINOMA; HEMATOPOIETIC STEM CELL; HEPATIC ENCEPHALOPATHY; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HERPES SIMPLEX VIRUS; HODGKIN DISEASE; HUMAN; JAUNDICE; KIDNEY FAILURE; LIVER DISEASE; LIVER FUNCTION; LIVER INJURY; LIVER ISCHEMIA; LIVER METABOLISM; LIVER NECROSIS; LIVER PAIN; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; NONHODGKIN LYMPHOMA; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION INJURY; REVIEW; TREATMENT PLANNING; VIRUS HEPATITIS;

ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; HEPATITIS, VIRAL, HUMAN; HUMANS; LIVER; LIVER DISEASES; NEOPLASMS; OPPORTUNISTIC INFECTIONS; PAIN;

EID: 46349095830     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2007.131136     Document Type: Review

References (100)

1. Lau GKK, Strasser SI, McDonald GB. Hepatitis virus infections in patients with cancer. In: Wingard JR, Bowden RA, eds. Management of infection in oncology patients. London: Martin Dunitz, 2003: 321-42.
2. Thursky KA, Worth LJ, Seymour JF, et al. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab. Br J Haematol 2006;132:3-12.
3. Iannitto E, Minardi V, Calvaruso G, et al. Hepatitis B virus reactivation and alemtuzumab therapy. Eur J Haematol 2005;74:254-8.
4. Dai M-S, Chao T-Y, Kao W-Y, et al. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann Hematol 2004;83:769-74.
5. Silva AE, McMahon BJ, Parkinson AJ, et al. Hepatitis B virus DNA in persons with isolated antibody to hepatitis B core antigen who subsequently received hepatitis B vaccine. Clin Infect Dis 1998;26:895-7.
6. Kohrt HE, Ouyang DL, Keeffe EB. Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Alimen Pharmacol Therap 2006;24:1003-16.
7. Carpenter PA, Huang ML, McDonald GB. Activation of occult hepatitis B from a seronegative patient after hematopoietic cell transplant: a cautionary tale. Blood 2002;99:4245-6.
8. van Burik JH, Leisenring W, Myerson D, et al. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis: An autopsy study of 355 patients. Medicine (Baltimore) 1998;77:246- 54.
9. Rossetti F, Brawner DL, Bowden RA, et al. Fungal liver infection in marrow transplant patients: prevalence at autopsy, predisposing factors, and clinical features. Clin Infect Dis 1995;20:801-11.
10. Ostrosky-Zeichner L, Alexander BD, Kett DH, et al. Multicenter clinical evaluation of the (1->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005;41:654-9.
11. Mennink-Kersten MASH, Donnelly JP, Verweij PE. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis 2004;4:349-57.
12. van Burik J-AH. Role of new antifungal agents in prophylaxis of mycoses in high risk patients. Curr Opin Infect Dis 2005;18:479- 83.
13. Ullmann AJ, Cornely OA, Burchardt A, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006;50:658-66.
14. Marotta G, Tozzi M, Sammassimo S, et al. Complete resolution of hepatic aspergillosis after non-myeloablative hematopoietic stem cell transplantation in a patient with acute myeloid leukemia. Hematology 2005;10:383-6.
15. Cordonnier C, Martino R, Trabasso P, et al. Mycobacterial infection: a difficult and late diagnosis in stem cell transplant recipients. Clin Infect Dis 2004;38:1229-36.
16. Navari RM, Sullivan KM, Springmeyer SC, et al. Mycobacterial infections in marrow transplant patients. Transplantation 1983;36:509-13.
17. MMWRR. The role of BCG vaccine in the prevention and control of tuberculosis in the United States. A joint statement by the Advisory Council for the Elimination of Tuberculosis and the Advisory Committee on Immunization Practices. Morbidity & Mortality Weekly Report Recommendations & Reports 1996;45:1-18.
18. Kornbluth AA, Danzig JB, Bernstein LH. Clostridium septicum infection and associated malignancy. Report of 2 cases and review of the literature. Medicine (Baltimore) 1989;68:30-7.
19. Gisbert JP, Garcia-Buey L, Pajares JM, et al. Systematic review: regression of lymphoproliferative disorders after treatment for hepatitis C infection. Aliment Pharmacol Therap 2005;21:653-62.
20. Delco F, Tchambaz L, Schlienger R, et al. Dose adjustment in patients with liver disease. Drug Safety 2005;28:529-45.
21. DeLeve LD. Cancer chemotherapy. In: Kaplowitz N, DeLeve LD, eds. Drug induced liver disease, second edn. New York: Marcel Dekker, 2007: 631-62.
22. Koren G, Beatty K, Seto A, et al. The effects of impaired liver function on the elimination of antineoplastic agents. Ann Pharmacother 1992;26:363-71.
23. King PD, Perry MC. Hepatotoxicity of chemotherapy. Oncologist 2001;6:162-76.
24. Leveque D, Jehl F. Clinical pharmacokinetics of vinorelbine. Clin Pharmacokinetics 1996;31:184-97.
25. Johnson PJ, Dobbs N, Kalayci C, et al. Clinical efficacy and toxicity of standard dose adriamycin in hyperbilirubinaemic patients with hepatocellular carcinoma: relation to liver tests and pharmacokinetic parameters. Br J Cancer 1992;65:751-5.
26. Twelves CJ, Richards MA, Smith P, et al. Epirubicin in breast cancer patients with liver metastases and abnormal liver biochemistry: initial weekly treatment followed by rescheduling and intensification. Ann Oncol 1991;2:663-6.
27. Hande KR, Wolff SN, Greco FA, et al. Etoposide kinetics in patients with obstructive jaundice. J Clin Oncol 1990;8:1101-7.
28. Evans WE, Relling MV, Rodman JH, et al. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. New Engl J Med 1998;338:499-505.
29. Slattery JT, Sanders JE, Buckner CD, et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 1995;16:31-42.
30. Radich JP, Gooley T, Bensinger W, et al. HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood 2003;102:31-5.
31. Furman WL, Baker SD, Pratt CB, et al. Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia. J Clin Oncol 1996;14:1504-11.
32. De Jonge ME, van den Bongard HJGD, Huitema ADR, et al. Bayesian pharmacokinetically guided dosing of paclitaxel in patients with non-small cell lung cancer. Clin Cancer Res 2004;10:2237-44.
33. de Jonge ME, Huitema AD, Tukker AC, et al. Accuracy, feasibility, and clinical impact of prospective bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy. Clin Cancer Res 2005;11:273-83.
34. Salinger DH, McCune JS, Ren AG, et al. Real-time dose adjustment of cyclophosphamide in a preparative regimen for hematopoietic cell transplant: a Bayesian pharmacokinetic approach. Clin Cancer Res 2006;12:4888-98.
35. Treon SP, Chabner BA. Concepts in use of high-dose methotrexate therapy. Clin Chem 1996;42:1322-9.
36. Mahadevan A, Kanegaonkar R, Hoskin PJ. Third space sequestration increases toxicity of fludarabine - a case report. Acta Oncol 1997;36:441.
37. Boyer TD. Management of the patient with drug-induced liver disease. In: Kaplowitz N, DeLeve LD, eds. Drug induced liver disease, second edn. New York: Informa Healthcare, 2007: 345-52.
38. Wadleigh M, Richardson PG, Zahrieh D, et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood 2003;102:1578-82.
39. McKoy JM, Angelotta C, Bennett CL, et al. Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leukemia Res 2007;31:599-604.
40. Etienne MC, Chatelut E, Pivot X, et al. Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis. Eur J Cancer 1998;34:92-7.
41. Wasserman E, Myara A, Lokiec F, et al. Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. Ann Oncol 1997;8:1049-51.
42. Paoluzzi L, Singh AS, Price DK, et al. Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. J Clin Pharmacol 2004;44:854-60.
43. Shulman HM, McDonald GB. Hepatic complications of hematopoietic cell transplantation. In: Gershwin ME, Vierling JM, Manns M, eds. Liver immunology: principles and practice. Totowa, NJ: Humana Press, 2007: 409-21.
44. McDonald GB. Management of hepatic disease following hematopoietic cell tranplant. Aliment Pharmacol Therap 2006;24:441-52.
45. Strasser SI, McDonald GB. Gastrointestinal and hepatic complications. In: Forman SJ, Appelbaum FR, Blume KG, Negrin R, eds. Thomas' hematopoietic cell transplantation, fourth edn. Malden, MA: Blackwell Publishing Inc., 2008: chapter 95. (in press).
46. Strasser SI, Myerson D, Spurgeon CL, et al. Hepatitis C virus infection after bone marrow transplantation: A cohort study with 10 year follow-up. Hepatology 1999;29:1893-9.
47. Peffault de Latour R, Levy V, Asselah T, et al. Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood 2004;103:1618-24.
48. Grant RM, Weitzman SS, Sherman CG, et al. Fulminant disseminated Varicella Zoster virus infection without skin involvement. J Clin Virol 2002;24:7-12.
49. de Jong MD, Weel JF, van Oers MH, et al. Molecular diagnosis of visceral herpes zoster. Lancet 2001;357:2101-2.
50. Neofytos D, Ojha A, Mookerjee B, et al. Treatment of adenovirus disease in stem cell transplant recipients with cidofovir. Biol Blood Marrow Transplant 2007;13:74-81.
51. Eddleston M, Peacock S, Juniper M, et al. Severe cytomegalovirus infection in immunocompetent patients. Clin Infect Dis 1997;24:52-6.
52. Kuribayashi K, Matsunaga T, Iyama S, et al. Human herpesvirus-6 hepatitis associated with cyclosporine-A encephalitis after bone marrow transplantation for chronic myeloid leukemia. Intern Med 2006;45:475-8.
53. Markin RS. Manifestations of Epstein-Barr virus-associated disorders in liver. Liver 1994;14:1-13.
54. Palanduz A, Yildirmak Y, Telhan L, et al. Fulminant hepatic failure and autoimmune hemolytic anemia associated with Epstein-Barr virus infection. J Infect 2002;45:96-8.
55. Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004;15:460-6.
56. Kanel GC. Histopathyology of drug-induced liver disease. In: Kaplowitz N, DeLeve LD, eds. Drug induced liver disease, second edn. New York: Informa Healthcare, 2007: 237-89.
57. Sempoux C, Horsmans Y, Geubel A, et al. Severe radiation-induced liver disease following localized radiation therapy for biliopancreatic carcinoma: activation of hepatic stellate cells as an early event. Hepatology 1997;26:128-34.
58. McDonald GB, Slattery JT, Bouvier ME, et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 2003;101:2043-8.
59. Moseley RH. Antibacterial and antifungal agents. In: Kaplowitz N, DeLeve LD, eds. Drug induced liver disease, second edn. New York: Informa Healthcare, 2007: 527-46.
60. Spengler U. Hepatic toxicity of antiviral agents. In: Kaplowitz N, DeLeve LD, eds. Drug induced liver disease, second edn. New York: Informa Healthcare, 2007: 567-591.
61. Lee WM, Ostapowicz G. Acetaminophen: pathology and clinical presentation of hepatotoxicity. In: Kaplowitz N, DeLeve LD, eds. Drug induced liver disease, second edn. New York: Informa Healthcare, 2007: 389-405.
62. Lewis JH. Nonsteroidal anti-inflammatory drugs and leukotriene receptor antagonists: pathology and clinical presentation of hepatotoxicity. In: Kaplowitz N, DeLeve LD, eds. Drug induced liver disease, second edn. New York: Informa Healthcare, 2007: 439-64.
63. Chitturi S, Farrell GC. Adverse effects of hormones and hormone antagonists on the liver. In: Kaplowitz N, DeLeve LD, eds. Drug induced liver disease, second edn. New York: Informa Healthcare, 2007: 707-22.
64. Liu LU, Schiano TD. Hepatotoxicity of herbal medicines, vitamins and natural hepatotoxins. In: Kaplowitz N, DeLeve LD, eds. Drug induced liver disease, second edn. New York: Informa Healthcare, 2007: 733-54.
65. Larrey D. Hepatotoxicity of psychotropic drugs and drugs of abuse. In: Kaplowitz N, DeLeve LD, eds. Drug induced liver disease, second edn. New York: Informa Healthcare, 2007: 507-26.
66. Kenna JG. Mechanism, pathology, and clinical presentation of hepatotoxicity of anesthetic agents. In: Kaplowitz N, DeLeve LD, eds. Drug induced liver disease, second edn. New York: Informa Healthcare, 2007: 465-84.
67. Pirmohamed M, Leeder SJ. Anticonvulsant agents. In: Kaplowitz N, DeLeve LD, eds. Drug induced liver disease, second edn. New York: Informa Healthcare, 2007: 485-505.
68. Henrion J, Schapira M, Luwaert R, et al. Hypoxic hepatitis: clinical and hemodynamic study in 142 consecutive cases. Medicine 2003;82:392-406.
69. Shulman HM, Gooley T, Dudley MD, et al. Utility of transvenous liver biopsies and wedged hepatic venous pressure measurements in sixty marrow transplant recipients. Transplantation 1995;59:1015- 22.
70. Deleve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: Sinusoidal obstruction syndrome (venocclusive disease). Semin Liver Dis 2002;22:27-41.
71. Gooley TA, Rajvanshi P, Schoch HG, et al. Serum bilirubin levels and mortality after myeloablative allogeneic hematopoietic cell transplantation. Hepatology 2005;41:345-52.
72. Bjornsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005;42:481-9.
73. Chand N, Sanyal AJ. Sepsis-induced cholestasis. Hepatology 2007;45:230-41.
74. Scharte M, Fink MP. Red blood cell physiology in critical illness. Crit Care Med 2003;31:S651-7.
75. Ruutu T, Eriksson B, Remes K, et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood 2002;100:1977-83.
76. Hubscher SG, Lumley MA, Elias E. Vanishing bile duct syndrome: a possible mechanism for intrahepatic cholestasis in Hodgkin's lymphoma. Hepatology 1993;17:70-7.
77. Grier JF, Cohen SW, Grafton WD, et al. Acute suppurative cholangitis associated with choledochal sludge. Am J Gastroenterol 1994;89:617-9.
78. Cabana MD, Alavi A, Berlin JA, et al. Morphine-augmented hepatobiliary scintigraphy: a meta-analysis. Nucl Med Commun 1995;16:1068-71.
79. Stucchi AF, Aarons CB, Becker JM. Surgical approaches to cancer in patients who have inflammatory bowel disease. Gastroenterol Clinics N Am 2006;35:641-73.
80. Abdalian R, Heathcote EJ. Sclerosing cholangitis: a focus on secondary causes. Hepatology 2006;44:1063-74.
81. Sandrasegaran K, Alazmi WM, Tann M, et al. Chemotherapy-induced sclerosing cholangitis. Clin Radiol 2006;61:670-8.
82. Alazmi WM, McHenry L, Watkins JL, et al. Chemotherapy-induced sclerosing cholangitis: long-term response to endoscopic therapy. J Clin Gastroenterol 2006;40:353-7.
83. Valla DC. Hepatic vein thrombosis (Budd-Chiari sydrome). Semin Liver Dis 2002;22:5-14.
84. Okuda K. Inferior vena cava thrombosis at its hepatic portion (obliterative hepatocavopathy). Semin Liver Dis 2002;22:15-26.
85. Richardson PG, Murakami C, Jin Z, et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplant with severe veno-occlusive disease and multi-system organ failure: response without significant toxicity in a high risk population and factors predictive of outcome. Blood 2002;100:4337-43.
86. Brancatelli G, Federle MP, Ambrosini R, et al. Cirrhosis: CT and MR imaging evaluation. Eur J Radiol 2007;61:57-69.
87. Yasmineh WG, Killeen AA, Filipovich AH. Conjugated hyperbilirubinemia and renal function in bone marrow transplant recipients. Arch Pathol Lab Med 1988;112:245-50.
88. Jacobson AF, Teefey SA, Lee SP, et al. Frequent occurrence of new hepatobiliary abnormalities after bone marrow transplantation: results of a prospective study using scintigraphy and sonography. Am J Gastroenterol 1993;88:1044-9.
89. Scheimberg IB, Pollock DJ, Collins PW, et al. Pathology of the liver in leukaemia and lymphoma. A study of 110 autopsies. Histopathology 1995;26:311-21.
90. McCullough KD, McDonald GB. Neutropenic enterocolitis. Curr Treat Op Infect Dis 2003;5:367-75.
91. Davern TJ. Hepatotoxicity of immunomodulating agents and the transplant situation. In: Kaplowitz N, DeLeve LD, eds. Drug induced liver disease, second edn. New York: Informa Healthcare, 2007: 663-81.
92. Groszmann RJ, Wongcharatrawee S. The hepatic venous pressure gradient: anything worth doing should be done right. Hepatology 2004;39:280-2.
93. Runyon BA. Ascites and spontaneous bacterial peritonitis. In: Feldman M, Friedman LS, Brandt LJ, eds. Sleisenger and Fordtran's gastrointestinal and liver disease, eighth edn. Philadelphia, PA: Saunders Elsevier, 2006: 1935-64.
94. Hogan WJ, Maris M, Storer B, et al. Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients. Blood 2004;103:76-82.
95. Frere P, Canivet JL, Gennigens C, et al. Hyperammonemia after high-dose chemotherapy and stem cell transplantation. Bone Marrow Transplant 2000;26:343-5.
96. Chiong MA, Bennetts BH, Strasser SI, et al. Fatal late-onset ornithine transcarbamylase deficiency after coronary artery bypass surgery. Med J Australia 2007;186:418-9.
97. Summar ML, Barr F, Dawling S, et al. Unmasked adult-onset urea cycle disorders in the critical care setting. Crit Care Clin 2005;21:S1-8.
98. Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003;349:474-85.
99. Andrade R-J, Robles M, Fernandez-Castaner A, et al. Assessment of drug-induced hepatotoxicity in clinical practice: a challenge for gastroenterologists. World J Gastroenterol 2007;13:329-40.
100. Guo JJ, Wigle PR, Lammers K, et al. Comparison of potentially hepatotoxic drugs among major US drug compendia. Research in Social & Administrative Pharmacy: RSAP 2005;1:460-79.